Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies
Despite some differences in pharmacokinetics and immunogenicity between CT-P13 SC received alone or in combination with immunosuppressants in patients with CD or UC, efficacy outcomes at week 54 or week 102 were generally comparable. The overall safety profile and incidence of systemic injection reactions were also comparable between monotherapy and combination therapy.
Authors
- Stephen B. Hanauer (ORCID: https://orcid.org/0000-0002-3268-932X)
- Jean‐Frédéric Colombel (ORCID: https://orcid.org/0000-0001-6472-249X)
- Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
- William J. Sandborn (ORCID: https://orcid.org/0000-0002-3314-7960)
- Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
- Stefan Schreiber (ORCID: https://orcid.org/0000-0003-2254-7771)
- Ga Hee Park
- Seul Gi Lee (ORCID: https://orcid.org/0000-0001-8186-0886)
- Sun Hee Lee
- Jong Min Kim (ORCID: https://orcid.org/0000-0002-5594-4864)
- Sung Hyun Kim
- Joon Ho Lee (ORCID: https://orcid.org/0000-0002-6272-3592)
- Chae Young Kim (ORCID: https://orcid.org/0000-0002-9905-6519)
- Yun Ju Bae (ORCID: https://orcid.org/0009-0002-3827-6742)
- Ju Hyun Lee
- Jimin Lee (ORCID: https://orcid.org/0000-0003-4922-4171)
Institutions
- Northwestern University (US)
- Vita-Salute San Raffaele University (IT)
- University of California San Diego (US)
- University Hospital Schleswig-Holstein (DE)
- Celltrion (South Korea) (KR)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Lübeck (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1093/ibd/izaf038
- Citations
- 6
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 10.90
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Mylan
- Celltrion
- Astellas Pharma
- Otsuka Pharmaceutical
- Mitsubishi Tanabe Pharma Corporation
- Dr. Falk Pharma
- Genentech
- Allergan
- Janssen Pharmaceuticals